AnthonyDerekSungMD
Hematology • Westwood, KSHematologic Oncology
Medical Instructor, Hematologic Malignancies and Cellular Therapy, Duke University Medical Center
Dr. Sung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2650 Shawnee Mission Pkwy
Westwood, KS 66205Phone+1 913-945-6674
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
Johns Hopkins UniversityInternship, Internal Medicine, 2008 - 2011
Harvard Medical SchoolClass of 2008
Certifications & Licensure
KS State Medical License 2024 - 2025
MO State Medical License 2024 - 2025
NC State Medical License 2011 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2021 Sep 01
- ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients Start of enrollment: 2020 Oct 14
- Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2 Start of enrollment: 2014 Sep 03
Roles: Sub-Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 42 citationsFecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational studyNiloufer Khan, Sarah Lindner, Antonio L.C. Gomes, Sean M. Devlin, Gunjan L. Shah
Blood. 2021-03-18 - 159 citationsThird-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.Zachariah DeFilipp, Jonathan U. Peled, Shuli Li, Jasmin Mahabamunuge, Zeina Dagher
Blood Advances. 2018-04-10 - 370 citationsMicrobiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell TransplantationJonathan U. Peled, Antonio L.C. Gomes, Sean M Devlin, Eric R. Littmann, Ying Taur
The New England Journal of Medicine. 2020-02-26
Press Mentions
More Options for People with Blood CancersMay 10th, 2023- FDA Panel Says Poziotinib’s Benefits Don’t Outweigh Risks in NSCLC With HER2 Exon 20 MutationsSeptember 22nd, 2022
- FDA Panel Puts PI3K Inhibitors for Blood Cancers on NoticeApril 22nd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
